Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its quarterly earnings data on Wednesday. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.05), Bloomberg Earnings reports. The firm had revenue of $71.00 million during the quarter, compared to the consensus estimate of $64.22 million. Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. Amphastar Pharmaceuticals’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 EPS.
Amphastar Pharmaceuticals opened at $17.18 on Friday, according to Marketbeat Ratings. Amphastar Pharmaceuticals has a 12 month low of $14.40 and a 12 month high of $20.45. The firm has a market capitalization of $829.73 million, a PE ratio of 77.39, a P/E/G ratio of 2.66 and a beta of 1.40. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.53 and a current ratio of 2.40.
A number of research firms have issued reports on AMPH. BidaskClub upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 10th. Finally, ValuEngine upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Amphastar Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.33.
In other news, CFO William J. Peters sold 3,250 shares of the stock in a transaction on Monday, July 9th. The stock was sold at an average price of $16.46, for a total value of $53,495.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jason B. Shandell sold 14,399 shares of the stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $16.77, for a total value of $241,471.23. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,649 shares of company stock worth $542,766. Insiders own 31.50% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Featured Article: Trading Strategy
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.